hydroxychloroquine has been researched along with Metabolic Syndrome in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 7.76 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. ( Elliott, JR; Kao, AH; Kuller, L; Manzi, S; Penn, SK; Schott, LL; Toledo, FG; Wasko, MC, 2010) |
| "To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 3.76 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. ( Elliott, JR; Kao, AH; Kuller, L; Manzi, S; Penn, SK; Schott, LL; Toledo, FG; Wasko, MC, 2010) |
| "Hydroxychloroquine (HCQ) use was found as a protective factor for CVD." | 1.43 | Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. ( Alpay-Kanıtez, N; Aral, O; Artim-Esen, B; Demir, S; Erer, B; Gül, A; İnanç, M; Kamalı, S; Öcal, L; Omma, A; Pehlivan, Ö; Şahinkaya, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, M | 1 |
| Kumar, M | 1 |
| Dutta, D | 1 |
| Soh, MC | 1 |
| Nelson-Piercy, C | 1 |
| Westgren, M | 1 |
| McCowan, L | 1 |
| Pasupathy, D | 1 |
| Demir, S | 1 |
| Artim-Esen, B | 1 |
| Şahinkaya, Y | 1 |
| Pehlivan, Ö | 1 |
| Alpay-Kanıtez, N | 1 |
| Omma, A | 1 |
| Erer, B | 1 |
| Kamalı, S | 1 |
| Gül, A | 1 |
| Aral, O | 1 |
| Öcal, L | 1 |
| İnanç, M | 1 |
| Penn, SK | 1 |
| Kao, AH | 1 |
| Schott, LL | 1 |
| Elliott, JR | 1 |
| Toledo, FG | 1 |
| Kuller, L | 1 |
| Manzi, S | 1 |
| Wasko, MC | 1 |
| Sahebari, M | 1 |
| Goshayeshi, L | 1 |
| Mirfeizi, Z | 1 |
| Rezaieyazdi, Z | 1 |
| Hatef, MR | 1 |
| Ghayour-Mobarhan, M | 1 |
| Akhlaghi, S | 1 |
| Sahebkar, A | 1 |
| Ferns, GA | 1 |
| Liu, SY | 1 |
| Guo, JY | 1 |
| Zhang, L | 1 |
| Liu, ZS | 1 |
| Zheng, ZH | 1 |
| Cheng, GY | 1 |
| Gao, GM | 1 |
| Zhang, X | 1 |
| Liu, GZ | 1 |
| Zeng, XF | 1 |
1 review available for hydroxychloroquine and Metabolic Syndrome
| Article | Year |
|---|---|
Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?
Topics: Adult; Antiphospholipid Syndrome; Cardiovascular Diseases; Female; Humans; Hydroxychloroquine; Lupus | 2017 |
5 other studies available for hydroxychloroquine and Metabolic Syndrome
| Article | Year |
|---|---|
Hydroxychloroquine in diabetes and dyslipidaemia: primum non nocere.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Enzyme Inhibitors; Human | 2020 |
Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Cardiovascular Diseases; Cross-Sectional | 2016 |
Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Cross-Sectional Studies; Diabetes Mellit | 2010 |
Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Femal | 2011 |
[Incidence of metabolic syndrome in systemic lupus erythematosus and its influence by glucocorticoids].
Topics: Adolescent; Adult; Case-Control Studies; Female; Glucocorticoids; Humans; Hydroxychloroquine; Incide | 2012 |